American Assets Inc. Invests $557,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

American Assets Inc. purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 5,000 shares of the specialty pharmaceutical company's stock, valued at approximately $557,000. Jazz Pharmaceuticals makes up approximately 0.2% of American Assets Inc.'s investment portfolio, making the stock its 13th largest holding.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC grew its stake in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock worth $92,000 after acquiring an additional 704 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Jazz Pharmaceuticals during the third quarter valued at approximately $625,000. Crossmark Global Holdings Inc. increased its holdings in shares of Jazz Pharmaceuticals by 23.6% during the third quarter. Crossmark Global Holdings Inc. now owns 5,083 shares of the specialty pharmaceutical company's stock valued at $567,000 after acquiring an additional 970 shares in the last quarter. CWA Asset Management Group LLC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth approximately $3,197,000. Finally, Philip James Wealth Mangement LLC bought a new position in Jazz Pharmaceuticals in the third quarter worth approximately $830,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on JAZZ. Needham & Company LLC restated a "buy" rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, November 7th. Wells Fargo & Company decreased their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating for the company in a report on Thursday, August 1st. Cantor Fitzgerald restated an "overweight" rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a report on Monday, August 19th. Finally, Royal Bank of Canada increased their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $175.00.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares of the company's stock, valued at $1,573,707.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

JAZZ stock traded up $0.62 during trading on Tuesday, reaching $127.74. 994,497 shares of the company were exchanged, compared to its average volume of 676,764. The company has a 50-day moving average of $111.23 and a two-hundred day moving average of $110.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 2.02. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a market capitalization of $7.89 billion, a price-to-earnings ratio of 17.99, a P/E/G ratio of 1.55 and a beta of 0.57.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.